3201 Beechleaf Court
About Syneos Health
Why Syneos Health? Join a game-changing global company that is reinventing the way therapies are developed and commercialized. Created through the merger of two industry leading companies - INC Research and inVentiv Health - we bring together more than 21,000 clinical and commercial minds to create better, smarter, faster ways to get biopharmaceutical therapies to patients. Teaming with some of the most talented professionals in the industry, you'll gain exposure and work in a dynamic environment where you'll be supported with comprehensive resources including emerging technologies, data, science and knowledge sharing. Grow your career with a global company committed to shortening the distance from lab to life.
Every aspect of Syneos Health fuels our Biopharmaceutical Acceleration Model -- and unlike traditional CROs and commercialization businesses, here, clinical and commercial are working together to accelerate customer success.
146 articles with Syneos Health
Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com.
Medidata NEXT London 2019: Blending the Best of Clinical Development, AI-Enabled Platform Demonstrations and Regulatory Compliance for Leaders in Life Sciences
Attend NEXT London 2019 to explore how the European Life Science landscape can embrace digital transformation to stay ahead of regulatory and market developments
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 Investing In Syneos Health, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Syneos Health, Inc. of the April 30, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
SYNEOS SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Syneos Health, Inc. - SYNH
Kahn Swick & Foti, LLC and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until April 30, 2019 to file lead plaintiff applications in a securities class action lawsuit against Syneos Health, Inc.
Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Syneos Health, Inc. - SYNH
The law firm of Kessler Topaz Meltzer & Check, LLP alerts investors that a securities fraud class action lawsuit has been filed against Syneos Health, Inc. on behalf of purchasers of Syneos securities between May 10, 2017 through February 27, 2019, inclusive.
SYNH LAWSUIT NOTICE: Rosen Law Firm Files Securities Class Action Lawsuit Against Syneos Health, Inc. - SYNH
Rosen Law Firm, a global investor rights law firm, announces it has filed a class action lawsuit on behalf of purchasers of the securities of Syneos Health, Inc. from May 10, 2017 through February 27, 2019, inclusive.
Syneos (SYNH) Investigation: Bernstein Liebhard LLP Announces First Investigation Of Syneos Health, Inc. - SYNH
Bernstein Liebhard LLP, a nationally acclaimed investor rights law firm, is investigating potential securities fraud claims on behalf of shareholders of Syneos Health, Inc. resulting from allegations that Syneos and/or its executives may have issued materially misleading business information to the investing public.
SYNH INVESTIGATIVE ALERT: Hagens Berman Alerts Syneos Health (SYNH) Investors to Investigation of Possible Improper Accounting
Hagens Berman Sobol Shapiro LLP alerts investors in Syneos Health, Inc. to the firm's investigation of possible improper accounting and possible violations of securities laws.
Manufacturing is the non-glamorous side of biopharma, although its impact on the economy shouldn’t be underestimated.
Cel-Sci Wins Breach of Contract Ruling against Clinical Research Organization inVentiv, Now Known as Syneos Health
CEL-SCI Corporation (NYSE American: CVM) announced today that after a four and a half year battle a decision has been delivered by the arbitrator in CEL-SCI's arbitration suit against clinical development giant inVentiv.
Syneos Health and Elligo Announce Strategic Collaboration to Advance Clinical Research for Real-World Patients
Syneos Health™ and Elligo Health Research are entering a strategic collaboration to mobilize a system of accelerated research to reach real-world patients.
After 35 years at the helm of Parexel International Corporation, co-founder Josef von Rickenbach is stepping down from his role as chief executive officer.
Syneos Health has announced the appointment of Lisa van Capelle as Chief Human Resources Officer.
The company is the the only fully integrated biopharmaceutical solutions organization combining a CRO and a CCO.
The word Syneos (pronounced SIN-ee-ohs) communicates the value of synchronizing clinical and commercial capabilities to accelerate customer performance.
INC Research/inVentiv Health Schedules Third Quarter 2017 Earnings Call for Thursday, November 9, 2017
Participants may access the conference call live via webcast on the Investor Relations section of the INC Research website.
Investigative Sites Honor INC Research/inVentiv Health With 2017 Society For Clinical Research Sites Eagle Award